Discounted Cash Flow (DCF) Analysis Levered
Castlight Health, Inc. (CSLT)
$2.05
0.00 (0.00%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 101.70 | 131.43 | 156.40 | 143.31 | 146.71 | 162.20 | 179.33 | 198.26 | 219.19 | 242.34 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -36.97 | -23.46 | -18.55 | -17.39 | -5.56 | -26.60 | -29.41 | -32.51 | -35.94 | -39.74 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -1.70 | -2.54 | -2.01 | -1.95 | -3.58 | -2.82 | -3.12 | -3.45 | -3.81 | -4.22 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -38.67 | -26 | -20.57 | -19.34 | -9.14 | -29.42 | -32.53 | -35.96 | -39.76 | -43.96 |
Weighted Average Cost Of Capital
| Share price | $ 2.05 |
|---|---|
| Beta | 1.660 |
| Diluted Shares Outstanding | 151.48 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 12.090 |
| Total Debt | 13.23 |
| Total Equity | 310.53 |
| Total Capital | 323.76 |
| Debt Weighting | 4.09 |
| Equity Weighting | 95.91 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 101.70 | 131.43 | 156.40 | 143.31 | 146.71 | 162.20 | 179.33 | 198.26 | 219.19 | 242.34 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.97 | -23.46 | -18.55 | -17.39 | -5.56 | -26.60 | -29.41 | -32.51 | -35.94 | -39.74 |
| Capital Expenditure | -1.70 | -2.54 | -2.01 | -1.95 | -3.58 | -2.82 | -3.12 | -3.45 | -3.81 | -4.22 |
| Free Cash Flow | -38.67 | -26 | -20.57 | -19.34 | -9.14 | -29.42 | -32.53 | -35.96 | -39.76 | -43.96 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -44.83 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -36.01 |
| Equity Value | - |
| Shares Outstanding | 151.48 |
| Equity Value Per Share | - |